PfizerPFE
PFE
About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Employees: 81,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
43% more first-time investments, than exits
New positions opened: 346 | Existing positions closed: 242
3% more funds holding in top 10
Funds holding in top 10: 40 [Q3] → 41 (+1) [Q4]
2% more funds holding
Funds holding: 2,873 [Q3] → 2,921 (+48) [Q4]
1.21% more ownership
Funds ownership: 64.68% [Q3] → 65.89% (+1.21%) [Q4]
6% less capital invested
Capital invested by funds: $106B [Q3] → $99.6B (-$6.34B) [Q4]
15% less call options, than puts
Call options by funds: $3.27B | Put options by funds: $3.87B
36% less repeat investments, than reductions
Existing positions increased: 919 | Existing positions reduced: 1,446
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
2%
downside
Avg. target
$26
4%
upside
High target
$28
15%
upside
4 analyst ratings
0 positive
0%
4 neutral
100%
0 negative
0%
UBS Trung Huynh 25% 1-year accuracy 2 / 8 met price target | 2%upside $25 | Neutral Maintained | 30 Apr 2025 |
Cantor Fitzgerald Carter Gould 39% 1-year accuracy 12 / 31 met price target | 2%downside $24 | Neutral Initiated | 22 Apr 2025 |
Goldman Sachs Asad Haider 100% 1-year accuracy 2 / 2 met price target | 2%upside $25 | Neutral Downgraded | 8 Apr 2025 |
UBS Colin Bristow 25% 1-year accuracy 3 / 12 met price target | 15%upside $28 | Neutral Maintained | 5 Feb 2025 |
Financial journalist opinion
Based on 147 articles about PFE published over the past 30 days
Positive
Zacks Investment Research
11 hours ago
Boost Your Portfolio With These 5 Low Price-to-Book Stocks
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.
Negative
The Motley Fool
14 hours ago
Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul
Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year. And that's after recovering recently -- it was down much more than that in early April when global tariffs were first announced.
Positive
The Motley Fool
15 hours ago
Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?
When a stock yields more than 5%, investors start to become skeptical about whether the payout is indeed safe. While it's tempting to want to believe that it can be safe and that it can be an excellent source of future dividend income, you also don't want to get burned and see that dividend get cut or suspended.
Positive
The Motley Fool
16 hours ago
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs.
Negative
Seeking Alpha
16 hours ago
Pfizer's Q1 Update May Mark A Bottom In The Stock
Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again.
Positive
Business Insider
20 hours ago
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away
Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US.
Positive
Zacks Investment Research
23 hours ago
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
Neutral
CNBC Television
1 day ago
Final Trade: XLF, ORLY, PFE, UBER
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Negative
Invezz
1 day ago
Pfizer could make ‘tremendous investments' in the US, but here's why it's choosing not to
Pfizer Inc. (NYSE: PFE) chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports under the Trump administration is discouraging the company from investing in the US.
Neutral
Seeking Alpha
1 day ago
Pfizer Inc. (PFE) Q1 2025 Earnings Call Transcript
Pfizer Inc. (NYSE:PFE ) Q1 2025 Results Conference Call April 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investment Relations Officer and Senior Vice President Dr. Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Chris Boshoff - Chief Scientific Officer Aamir Malik - Chief U.S. Commercial Officer and Executive Vice President Alexandre de Germay - Executive Vice President & Chief International Commercial Officer Andrew Baum - Chief Strategy & Innovation Officer and Executive Vice President Conference Call Participants Vamil Divan - Guggenheim Evan Seigerman - BMO Capital Markets Tim Anderson - Bank of America Steve Scala - Cowen Umer Raffat - Evercore ISI Chris Schott - JPMorgan Geoff Meacham - Citi Trung Huynh - UBS Kerry Holford - Berenberg Akash Tewari - Jefferies Terence Flynn - Morgan Stanley Dave Reisinger - Leerink Mohit Bansal - Wells Fargo Courtney Breen - Bernstein Assad Haider - Goldman Sachs Operator Good day, everyone, and welcome to Pfizer's First Quarter 2025 Earnings Conference Call. Today's call is being recorded.
Charts implemented using Lightweight Charts™